RCC exhibits resistance to standard chemotherapy and radiotherapy; however, a complete response has been observed following high-dose interleukin-2 (IL-2) and interferon-alpha (IFN-α) immunotherapy [31]. The gene discussed is IL2; the disease is renal cell carcinoma.